April 2020 PMID 32344682

Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia.

Brigitte Tardy, Thomas Lecompte, François Mullier, Caroline Vayne, Claire Pouplard

Full text PDF Download social card

Mentions

Peak: 2 in Apr 2024

across 2 sources since Mar 2022

Extended reach

15,343

potential audience

Total likes

Video views

2,207

Mentions per month

Mar 2022 – Aug 2025

Where it's discussed

X / Twitter4 posts
YouTube2 videos

AI synopsis

What people are saying

Various discussions highlight the publication’s relevance, with phrases like 'Check out the high-citation review' indicating recognition of its importance. The tone remains informational, emphasizing diagnostic challenges and validation, shaping an understanding of its meaningful clinical impact without overly emotional language.

AgreementModerate agreement

Most discussions acknowledge the importance of accurately diagnosing HIT, suggesting general agreement with the publication’s findings.

InterestNeutral interest

The posts display neutral interest, with some titles referencing the significance of the research without deep engagement.

EngagementModerate engagement

Comments include recommendations to review related studies and mention of specific diagnostic methods, indicating moderate engagement.

ImpactModerate impact

The emphasis on diagnostic accuracy and references to influential reviews imply recognized significance in the medical community.

Abstract in brief

Heparin-induced thrombocytopenia (HIT) is an immune reaction where platelet-activating antibodies target PF4-polyanion complexes, leading to increased risk of blood clots.
Functional platelet activation assays are more specific for diagnosing HIT because they measure the actual ability of patient sera to activate healthy donor platelets in the presence of heparin, with tests like the serotonin release assay (SRA) being the gold standard.
Despite their accuracy, these assays have limitations such as sensitivity and complexity, and require strict testing conditions, including proper preanalytical procedures, specific donor platelet selection, and use of controls to ensure reliable results.

Read the full abstract

All mentions

Understanding Heparin-Induced Thrombocytopenia and VITT Risks

Stago Group - Official Channel · Dec 15, 2022 1,934 views

Understanding Heparin-Induced Thrombocytopenia Risks and Insights

In this episode, Dr. Caroline Vayne from Tours University Hospital discusses heparin-induced thrombocytopenia, a serious thrombotic condition. We delve into clinical features, current understanding, and the importance…

Stago Group - Official Channel · Mar 1, 2022 273 views

Nathalia Le Hen

@NathaliaLeHen · X

@knowmedge ✅¹⁴

Aug 14, 2025 · 5 likes · 2,824 followers View post →

Raghav Agrawal

@impactology · X

Evaluation of laboratory assays for anti‐platelet factor 4 antibodies after ChAdOx1 nCOV‐19 vaccination https://t.co/57ZEKiQvt8

Apr 30, 2024 · 3,378 followers View post →